Refractory Folliculitis Decalvans Treated With Adalimumab: A Case Series of 23 Patients

March 2022 in “ Journal of the American Academy of Dermatology ”

Matilde Iorizzo, Michela Starace, Sergio Vañó‐Galván, Bianca Maria Piraccini, Pascal Reygagne, Lidia Rudnicka, Tatiana Silyuk, Rodney Sinclair, Antonellá Tosti

folliculitis decalvans adalimumab tumor necrosis factor inflammatory cytokine Humira

Studysummary Adalimumab improved folliculitis decalvans in most patients.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

Folliculitis Decalvans: Effectiveness of Therapies and Prognostic Factors in a Multicenter Series of 60 Patients with Long-Term Follow-Up

research Folliculitis Decalvans: Effectiveness of Therapies and Prognostic Factors in a Multicenter Series of 60 Patients with Long-Term Follow-Up

41 citations , June 2018 in “Journal of The American Academy of Dermatology”

This study examined the therapeutic response to folliculitis decalvans treatments among 60 patients and found that earlier disease onset was linked to more severe cases, while a combination of rifampicin, clindamycin, tetracyclines, and intralesional steroids was most effective in controlling symptoms.